Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer

Giuseppe Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Di Bonito, M. D'Aiuto, A. Petrillo, S. Lastoria, C. Siani, G. Comella, G. D'Aiuto

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Findings from our previously published phase II study showed a high pathologic complete remission (pCR) rate in patients with triple-negative large operable breast cancer after the administration of eight cisplatin-epirubicin-paclitaxel (PET) weekly cycles. The safety and efficacy data of the initial population were updated, with inclusion of additional experience with the same therapy. Methods: Patients with triple-negative large operable breast cancer (T2-T3 N0-1; T > 3 cm) received eight preoperative weekly cycles of cisplatin 30 mg/m2, epirubicin 50 mg/m2, paclitaxel (Taxol) 120 mg/m2, with granulocyte colony-stimulating factor (5 μg/kg days 3-5) support. Results: Overall 74 consecutive patients (T2/T3 = 35/39; N0/N+ = 26/48) were treated, from May 1999 to May 2008. At pathological assessment, 46 women (62%; 95% confidence interval 50-73) showed pCR in both breast and axilla. At a 41-month median follow-up (range 3-119), 13 events (nine distant metastases) had occurred, 5-year projected disease-free survival (DFS) and distant disease-free survival being 76% and 84%, respectively. Five-year DFS was 90% and 56% in pCRs and non-pCRs, respectively. Severe neutropenia and anemia occurred in 23 (31%) and eight (10.8%) patients, respectively. Severe non-hematological toxicity was recorded in

Original languageEnglish
Pages (from-to)1185-1192
Number of pages8
JournalAnnals of Oncology
Volume20
Issue number7
DOIs
Publication statusPublished - 2009

Fingerprint

Epirubicin
Granulocyte Colony-Stimulating Factor
Breast Neoplasms
Disease-Free Survival
Paclitaxel
Axilla
Neutropenia
Cisplatin
Anemia
Breast
Confidence Intervals
Neoplasm Metastasis
Safety
TP protocol
Population
Therapeutics

Keywords

  • Cisplatin
  • Epirubicin
  • Operable breast cancer
  • Paclitaxel
  • Triple negative
  • Weekly administration

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{99e833d9beff4669888c5c880076705d,
title = "Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer",
abstract = "Background: Findings from our previously published phase II study showed a high pathologic complete remission (pCR) rate in patients with triple-negative large operable breast cancer after the administration of eight cisplatin-epirubicin-paclitaxel (PET) weekly cycles. The safety and efficacy data of the initial population were updated, with inclusion of additional experience with the same therapy. Methods: Patients with triple-negative large operable breast cancer (T2-T3 N0-1; T > 3 cm) received eight preoperative weekly cycles of cisplatin 30 mg/m2, epirubicin 50 mg/m2, paclitaxel (Taxol) 120 mg/m2, with granulocyte colony-stimulating factor (5 μg/kg days 3-5) support. Results: Overall 74 consecutive patients (T2/T3 = 35/39; N0/N+ = 26/48) were treated, from May 1999 to May 2008. At pathological assessment, 46 women (62{\%}; 95{\%} confidence interval 50-73) showed pCR in both breast and axilla. At a 41-month median follow-up (range 3-119), 13 events (nine distant metastases) had occurred, 5-year projected disease-free survival (DFS) and distant disease-free survival being 76{\%} and 84{\%}, respectively. Five-year DFS was 90{\%} and 56{\%} in pCRs and non-pCRs, respectively. Severe neutropenia and anemia occurred in 23 (31{\%}) and eight (10.8{\%}) patients, respectively. Severe non-hematological toxicity was recorded in",
keywords = "Cisplatin, Epirubicin, Operable breast cancer, Paclitaxel, Triple negative, Weekly administration",
author = "Giuseppe Frasci and P. Comella and M. Rinaldo and G. Iodice and {Di Bonito}, M. and M. D'Aiuto and A. Petrillo and S. Lastoria and C. Siani and G. Comella and G. D'Aiuto",
year = "2009",
doi = "10.1093/annonc/mdn748",
language = "English",
volume = "20",
pages = "1185--1192",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer

AU - Frasci, Giuseppe

AU - Comella, P.

AU - Rinaldo, M.

AU - Iodice, G.

AU - Di Bonito, M.

AU - D'Aiuto, M.

AU - Petrillo, A.

AU - Lastoria, S.

AU - Siani, C.

AU - Comella, G.

AU - D'Aiuto, G.

PY - 2009

Y1 - 2009

N2 - Background: Findings from our previously published phase II study showed a high pathologic complete remission (pCR) rate in patients with triple-negative large operable breast cancer after the administration of eight cisplatin-epirubicin-paclitaxel (PET) weekly cycles. The safety and efficacy data of the initial population were updated, with inclusion of additional experience with the same therapy. Methods: Patients with triple-negative large operable breast cancer (T2-T3 N0-1; T > 3 cm) received eight preoperative weekly cycles of cisplatin 30 mg/m2, epirubicin 50 mg/m2, paclitaxel (Taxol) 120 mg/m2, with granulocyte colony-stimulating factor (5 μg/kg days 3-5) support. Results: Overall 74 consecutive patients (T2/T3 = 35/39; N0/N+ = 26/48) were treated, from May 1999 to May 2008. At pathological assessment, 46 women (62%; 95% confidence interval 50-73) showed pCR in both breast and axilla. At a 41-month median follow-up (range 3-119), 13 events (nine distant metastases) had occurred, 5-year projected disease-free survival (DFS) and distant disease-free survival being 76% and 84%, respectively. Five-year DFS was 90% and 56% in pCRs and non-pCRs, respectively. Severe neutropenia and anemia occurred in 23 (31%) and eight (10.8%) patients, respectively. Severe non-hematological toxicity was recorded in

AB - Background: Findings from our previously published phase II study showed a high pathologic complete remission (pCR) rate in patients with triple-negative large operable breast cancer after the administration of eight cisplatin-epirubicin-paclitaxel (PET) weekly cycles. The safety and efficacy data of the initial population were updated, with inclusion of additional experience with the same therapy. Methods: Patients with triple-negative large operable breast cancer (T2-T3 N0-1; T > 3 cm) received eight preoperative weekly cycles of cisplatin 30 mg/m2, epirubicin 50 mg/m2, paclitaxel (Taxol) 120 mg/m2, with granulocyte colony-stimulating factor (5 μg/kg days 3-5) support. Results: Overall 74 consecutive patients (T2/T3 = 35/39; N0/N+ = 26/48) were treated, from May 1999 to May 2008. At pathological assessment, 46 women (62%; 95% confidence interval 50-73) showed pCR in both breast and axilla. At a 41-month median follow-up (range 3-119), 13 events (nine distant metastases) had occurred, 5-year projected disease-free survival (DFS) and distant disease-free survival being 76% and 84%, respectively. Five-year DFS was 90% and 56% in pCRs and non-pCRs, respectively. Severe neutropenia and anemia occurred in 23 (31%) and eight (10.8%) patients, respectively. Severe non-hematological toxicity was recorded in

KW - Cisplatin

KW - Epirubicin

KW - Operable breast cancer

KW - Paclitaxel

KW - Triple negative

KW - Weekly administration

UR - http://www.scopus.com/inward/record.url?scp=67650382241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650382241&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn748

DO - 10.1093/annonc/mdn748

M3 - Article

VL - 20

SP - 1185

EP - 1192

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -